The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
Open accessAbstract
Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members. This phase II, open-label, single-arm study explored afatinib activity in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients progressing after trastuzumab treatment. Patients had stage IIIB/IV HER2-positive metastatic breast cancer, with progression following trastuzumab or trastuzumab intolerance and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients received 50 mg afatinib once-daily until disease progression. Primary endpoint was objective response rate (Response Evaluation Criteria in Solid Tumors 1.0), with tumor assessments every 8 weeks. Forty-one patients were treated. Patients had received a median of three prior chemotherapy lines (range, 0-15) and 68.3% had received trastuzumab for >1 year. Four patients (10% of 41 treated; 11% of evaluable patients) had partial response. Fifteen patients (37% of 41) had stable disease as best response and 19 (46% of 41) achieved clinical benefit. Median progression-free survival was 15.1 weeks (95% confidence interval [CI]: 8.1-16.7); median overall survival was 61.0 weeks (95% CI: 56.7-not evaluable). Most frequent common terminology criteria for adverse events grade 3 treatment-related adverse events were diarrhea (24.4%) and rash (9.8%). Afatinib monotherapy was associated with promising clinical activity in extensively pretreated HER2-positive breast cancer patients who had progressed following trastuzumab treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eskens, F. A. L. M., Mom, C. H., Planting, A. S. T., Gietema, J. A., Amelsberg, A., Huisman, H., van Doorn, L., Burger, H., Stopfer, P., Verweij, J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604108 · Cited by 234
Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation
Anido, J., Scaltriti, M., Bech Serra, J. J., Josefat, B. S., Rojo Todo, F., Baselga, J., & Arribas, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601191 · Cited by 231
Cited by
Iqbal, N., & Iqbal, N. (2014) · Molecular Biology International · doi:10.1155/2014/852748 · Cited by 1,381
Metastatic and triple-negative breast cancer: challenges and treatment options
Al-Mahmood, S., Sapiezynski, J., Garbuzenko, O. B., & Minko, T. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0551-3 · Cited by 524
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Wang, J., & Xu, B. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0069-2 · Cited by 393
Targeting RTK Signaling Pathways in Cancer
Regad, T. (2015) · Cancers · doi:10.3390/cancers7030860 · Cited by 380
Afatinib: First Global Approval
Dungo, R. T., & Keating, G. M. (2013) · Drugs · doi:10.1007/s40265-013-0111-6 · Cited by 329
Metadata
- Authors
- Lin, N. U., Winer, E. P., Wheatley, D., Carey, L. A., Houston, S., Mendelson, D., Munster, P., Frakes, L., Kelly, S., Garcia, A. A., Cleator, S., Uttenreuther-Fischer, M., Jones, H., Wind, S., Vinisko, R., & Hickish, T.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2012-03-15
- Volume
- 133
- Issue
- 3
- Pages
- 1057-1065
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2088145034
- Cited by
- 195
- References
- 2
- FWCI
- 14.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. https://app.cochat.ai/papers/10.1007/s10549-012-2003-y
- The paper
- Lin, N. U., Winer, E. P., Wheatley, D., Carey, L. A., Houston, S., Mendelson, D., Munster, P., Frakes, L., Kelly, S., Garcia, A. A., Cleator, S., Uttenreuther-Fischer, M., Jones, H., Wind, S., Vinisko, R., & Hickish, T. (2012). A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-012-2003-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.